136 related articles for article (PubMed ID: 38488054)
1. Ovarian Cancer Risk-Reduction and Screening in
DiSilvestro JB; Haddad J; Robison K; Beffa L; Laprise J; Scalia-Wilbur J; Raker C; Clark MA; Lokich E; Hofstatter E; Dalela D; Brown A; Bradford L; Toland M; Stuckey A
J Womens Health (Larchmt); 2024 May; 33(5):624-628. PubMed ID: 38488054
[No Abstract] [Full Text] [Related]
2. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.
Botkin JR; Smith KR; Croyle RT; Baty BJ; Wylie JE; Dutson D; Chan A; Hamann HA; Lerman C; McDonald J; Venne V; Ward JH; Lyon E
Am J Med Genet A; 2003 Apr; 118A(3):201-9. PubMed ID: 12673648
[TBL] [Abstract][Full Text] [Related]
3. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
4. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
5. Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
Chen Y; Bancroft E; Ashley S; Arden-Jones A; Thomas S; Shanley S; Saya S; ; Wakeling E; Eeles R
Fam Cancer; 2014 Jun; 13(2):197-203. PubMed ID: 24389956
[TBL] [Abstract][Full Text] [Related]
6. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.
Beattie MS; Crawford B; Lin F; Vittinghoff E; Ziegler J
Genet Test Mol Biomarkers; 2009 Feb; 13(1):51-6. PubMed ID: 19309274
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
Schwartz MD; Isaacs C; Graves KD; Poggi E; Peshkin BN; Gell C; Finch C; Kelly S; Taylor KL; Perley L
Cancer; 2012 Jan; 118(2):510-7. PubMed ID: 21717445
[TBL] [Abstract][Full Text] [Related]
8. Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.
Ghezelayagh TS; Stewart LE; Norquist BM; Bowen DJ; Yu V; Agnew KJ; Pennington KP; Swisher EM
Fam Cancer; 2020 Apr; 19(2):143-151. PubMed ID: 32096072
[TBL] [Abstract][Full Text] [Related]
9. Family planning in carriers of BRCA1 and BRCA2 pathogenic variants.
Haddad JM; Robison K; Beffa L; Laprise J; ScaliaWilbur J; Raker CA; Clark MA; Hofstatter E; Dalela D; Brown A; Bradford L; Toland M; Stuckey A
J Genet Couns; 2021 Dec; 30(6):1570-1581. PubMed ID: 33904624
[TBL] [Abstract][Full Text] [Related]
10. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation.
Wainberg S; Husted J
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):1989-95. PubMed ID: 15598752
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
Schrijver LH; Antoniou AC; Olsson H; Mooij TM; Roos-Blom MJ; Azarang L; Adlard J; Ahmed M; Barrowdale D; Davidson R; Donaldson A; Eeles R; Evans DG; Frost D; Henderson A; Izatt L; Ong KR; Bonadona V; Coupier I; Faivre L; Fricker JP; Gesta P; van Engelen K; Jager A; Menko FH; Mourits MJE; Singer CF; Tan YY; Foretova L; Navratilova M; Schmutzler RK; Ellberg C; Gerdes AM; Caldes T; Simard J; Olah E; Jakubowska A; Rantala J; Osorio A; Hopper JL; Phillips KA; Milne RL; Beth Terry M; Noguès C; Engel C; Kast K; Goldgar DE; van Leeuwen FE; Easton DF; Andrieu N; Rookus MA;
Am J Obstet Gynecol; 2021 Jul; 225(1):51.e1-51.e17. PubMed ID: 33493488
[TBL] [Abstract][Full Text] [Related]
12. Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.
Mannis GN; Fehniger JE; Creasman JS; Jacoby VL; Beattie MS
JAMA Intern Med; 2013 Jan; 173(2):96-103. PubMed ID: 23247828
[TBL] [Abstract][Full Text] [Related]
13. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
Krassuski L; Vennedey V; Stock S; Kautz-Freimuth S
BMC Med Inform Decis Mak; 2019 Aug; 19(1):154. PubMed ID: 31370837
[TBL] [Abstract][Full Text] [Related]
15. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
16. An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.
Madorsky-Feldman D; Sklair-Levy M; Perri T; Laitman Y; Paluch-Shimon S; Schmutzler R; Rhiem K; Lester J; Karlan BY; Singer CF; Van Maerken T; Claes K; Brunet J; Izquierdo A; Teulé A; Lee JW; Kim SW; Arun B; Jakubowska A; Lubinski J; Tucker K; Poplawski NK; Varesco L; Bonelli LA; Buys SS; Mitchell G; Tischkowitz M; Gerdes AM; Seynaeve C; Robson M; Kwong A; Tung N; Tessa N; Domchek SM; Godwin AK; Rantala J; Arver B; Friedman E
Breast Cancer Res Treat; 2016 Jun; 157(2):319-327. PubMed ID: 27117159
[TBL] [Abstract][Full Text] [Related]
17. Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.
Park JS; Lee ST; Han JW; Kim TI; Nam EJ; Park HS
Clin Breast Cancer; 2018 Oct; 18(5):362-373.e1. PubMed ID: 29673794
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
[TBL] [Abstract][Full Text] [Related]
19. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
[TBL] [Abstract][Full Text] [Related]
20. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
